| Name | Title | Contact Details |
|---|---|---|
Jamie Sischo |
Vice President Contracts and Proposals and Government Business Development | Profile |
Asif Sayani |
General Counsel | Profile |
AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Health is an innovative technology company whose mission is to improve health outcomes, lower costs and foster a more consumer-centric healthcare industry. We own and operate the internet`s largest group of condition-specific social communities serving over 1.5 million registered members across a broad set of chronic health conditions. Each site leverages social and mobile elements to empower patients and caregivers with connections to supportive peers, personalized information, and relevant products and services. We also offer access to affordable prescription medications, either home-delivered, or through our pharmacy network.
Drug Transport, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Molecular NeuroImaging is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.